FDAnews Drug Daily Bulletin

NEW DATA HIGHLIGHT ANTI-HCV ACTIVITY OF INVESTIGATIONAL ORAL HEPATITIS C PROTEASE INHIBITOR VX-950

April 27, 2006
A A

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that researchers will present new data supporting clinical development of VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor being developed for the treatment of hepatitis C, at the 41st Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna. CNW Group (http://www.newswire.ca/en/releases/archive/April2006/26/c0809.html)